Ayşen Hazal Buran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayşen Hazal Buran has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Anık
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Aydın Adnan Menderes University, Aydın, Turkiye
1 shared publication - Ayhan Abacı
Dokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Turkey
1 shared publication - Ece Böber
Dokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Turkey
1 shared publication - Gözde Akın Kağızmanlı
Dokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Türkiye
1 shared publication - Korcan Demir
Dokuz Eylul University Faculty of Medicine
1 shared publication - Kübra Yüksek Acinikli
Dokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Türkiye
1 shared publication
Latest Publications
- 12 July 2023
- Published by Springer Nature in Hormones
- Vol. 22 (3) , 501-506
Which method is more effective in predicting adult height in pubertal girls treated with gonadotropin-releasing hormone agonist?
Purpose The aim of the present study was to determine the efficiency of three different predictive models [Bayley-Pinneau (BP), Roche-Wainer-Thissen (RWT), and Tanner-Whitehouse 2 (TW2)] by comparing their predictions with near-adult height data of girls receiving gonadotropin-releasing hormone agonist (GnRHa) therapy. Methods Clinical findings were retrospectively analyzed. Bone ages obtained before treatment were evaluated from left hand and wrist radiographs by three researchers. Predicted adult height (PAH) was calculated using the BP, RWT, and TW2 methods for each patient at the beginning of therapy. Results The median age at diagnosis of the 48 patients included in the study was 8.8 (8.9-9.3) years. There was no significant difference between the mean bone ages evaluated separately with the Greulich-Pyle atlas and the TW3-RUS method (p=0.34). Among the PAH methods, only PAH measured by the BP method was very close to and no different from near adult height (NAH) [159.8±6.3 vs. 158.8±9.3 cm. p=0.3; (-0.5±1.1) vs. (-0.7±1.6) standard deviation score, p=0.1]. Accordingly, the BP method was found to be the most accurate prediction tool in girls with puberty treated with GnRHa. Conclusion The BP method is more effective at predicting adult height than the RWT and TW2 methods in female patients who will receive GnRHa treatment.
- 12 July 2023
- Published by Springer Nature in Hormones
- Vol. 22 (3) , 501-506
Which method is more effective in predicting adult height in pubertal girls treated with gonadotropin-releasing hormone agonist?
Purpose The aim of the present study was to determine the efficiency of three different predictive models [Bayley-Pinneau (BP), Roche-Wainer-Thissen (RWT), and Tanner-Whitehouse 2 (TW2)] by comparing their predictions with near-adult height data of girls receiving gonadotropin-releasing hormone agonist (GnRHa) therapy. Methods Clinical findings were retrospectively analyzed. Bone ages obtained before treatment were evaluated from left hand and wrist radiographs by three researchers. Predicted adult height (PAH) was calculated using the BP, RWT, and TW2 methods for each patient at the beginning of therapy. Results The median age at diagnosis of the 48 patients included in the study was 8.8 (8.9-9.3) years. There was no significant difference between the mean bone ages evaluated separately with the Greulich-Pyle atlas and the TW3-RUS method (p=0.34). Among the PAH methods, only PAH measured by the BP method was very close to and no different from near adult height (NAH) [159.8±6.3 vs. 158.8±9.3 cm. p=0.3; (-0.5±1.1) vs. (-0.7±1.6) standard deviation score, p=0.1]. Accordingly, the BP method was found to be the most accurate prediction tool in girls with puberty treated with GnRHa. Conclusion The BP method is more effective at predicting adult height than the RWT and TW2 methods in female patients who will receive GnRHa treatment.